DPYSL2 and early-onset autosomal dominant Alzheimer disease: Multiple studies have confirmed the beneficial effects of HupA in the treatment of Alzheimer's disease (AD) (Xu et al., 1995; Yang et al., 2013), while our recent study further demonstrated the inhibitory role of HupA in CRMP2 S522 phosphorylation (Wang et al., 2024), which coincides with the phenotype of the CRMP2 KI mutant.